Security
Cerenome, Inc. Common Stock · CNSY
CNSYNASDAQCommon stockCurrentCIK 1095981Updated Oct 6, 2026
Name history
PLUS THERAPEUTICS, INC. · through Jul 1, 2026CYTORI THERAPEUTICS, INC. · through Aug 2, 2019MACROPORE INC · through Jul 5, 2005
CNSY price & chart
Loading TradingView…
NASDAQ:CNSY on TradingView ↗About the company
Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (“CNS”) cancers. Our novel radiotherapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes within nanoliposomes and microspheres. Our formulations are intended to achieve elevated patient-absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal tissue/organ exposure and improved safety margins.
In the news
Cerenome Reports Second Quarter 2026 Financial Results and Business Update ↗
Recent filings
Other Events
Items 8.01, 9.01
D filing
Items 06b
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 2.03, 3.02, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 16,325,000Source | 6,633,000Source | 11,388,000Source | 23,867,000Source |
| Property, Plant and Equipment, NetUSD | 257,000Source | 448,000Source | 906,000Source | 1,324,000Source |
| GoodwillUSD | 372,000Source | 372,000Source | 372,000Source | 372,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,256,000Source | 76,000Source | 8,554,000Source | 18,120,000Source |
| Assets, CurrentUSD | 15,170,000Source | 5,259,000Source | 9,834,000Source | 21,817,000Source |
| Operating Lease, Right-of-Use AssetUSD | 70,000Source | 73,000Source | 202,000Source | 248,000Source |
| Other Assets, NoncurrentUSD | 123,000Source | 12,000Source | 32,000Source | 12,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 12,329,000Source | 15,582,000Source | 12,736,000Source | 17,422,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 139,000Source | 6,000Source | 5,000Source | 34,000Source |
| Additional Paid in CapitalUSD | 520,222,000Source | 485,024,000Source | 479,274,000Source | 473,596,000Source |
| Retained Earnings (Accumulated Deficit)USD | -515,865,000Source | -493,479,000Source | -480,501,000Source | -467,185,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,996,000Source | -8,949,000Source | -1,348,000Source | 6,445,000Source |
| Liabilities and EquityUSD | 16,325,000Source | 6,633,000Source | 11,388,000Source | 23,867,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 12,314,000Source | 15,551,000Source | 10,727,000Source | 11,852,000Source |
| Operating Lease, Liability, CurrentUSD | 56,000Source | 44,000Source | 120,000Source | 110,000Source |
| Accounts Payable, CurrentUSD | 3,276,000Source | 9,474,000Source | 4,758,000Source | 8,364,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,000Source | 31,000Source | 85,000Source | 141,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 13,100,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 3,976,000Source | 1,608,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 3,786,000Source |
| Short-term InvestmentsUSD | 4,356,000Source | 3,530,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 445,000Source | 723,000Source | 628,000Source | 619,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,540,000Source | 550,000Source | 569,000Source | 606,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -20,775,000Source | -10,554,000Source | -12,851,000Source | -12,972,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -854,000Source | -4,111,000Source | -160,000Source | -759,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 67,000Source | 146,000Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 30,311,000Source | 6,187,000Source | 3,445,000Source | 13,451,000Source |
| Repayments of Long-term DebtUSD | — | 3,996,000Source | 1,608,000Source | 1,608,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,682,000Source | -8,478,000Source | -9,566,000Source | -280,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 32,000Source | 222,000Source | 327,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 20,000Source | 190,000Source | 389,000Source |
| Amortization of Intangible AssetsUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 13,100,000Source | — | — | — |
| DepreciationUSD | 200,000Source | 600,000Source | 600,000Source | 500,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | 16,000Source | — | -2,000Source | 0Source |
| General and Administrative ExpenseUSD | 12,132,000Source | 9,939,000Source | 8,544,000Source | 10,238,000Source |
| GoodwillUSD | 372,000Source | 372,000Source | 372,000Source | 372,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 548,000Source | 179,000Source | — | — |
| Investment Income, InterestUSD | 116,000Source | 273,000Source | 400,000Source | 147,000Source |
| Net Income (Loss) Attributable to ParentUSD | -22,386,000Source | -12,978,000Source | -13,316,000Source | -20,275,000Source |
| Nonoperating Income (Expense)USD | -7,088,000Source | 1,717,000Source | 5,000Source | -563,000Source |
| Operating ExpensesUSD | 20,511,000Source | 20,519,000Source | 18,234,000Source | 19,936,000Source |
| Operating Lease, ExpenseUSD | 400,000Source | 200,000Source | 200,000Source | 200,000Source |
| Payments of Financing CostsUSD | 2,250,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 22,615,000Source | — | 5,527,000Source | 15,059,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 5,213,000Source | 5,824,000Source | — | — |
| Operating Income (Loss)USD | -15,298,000Source | -14,695,000Source | -13,321,000Source | -19,712,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -22,386,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -22,386,000Source | -12,978,000Source | -13,316,000Source | -20,275,000Source |
| Earnings Per Share, BasicUSD per share | -0.29Source | -1.95Source | -4.24Source | -0.77Source |
| Earnings Per Share, DilutedUSD per share | -0.29Source | -2.34Source | -4.24Source | -0.77Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 77,804,612Source | 6,640,251Source | 3,140,925Source | 26,255,256Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 77,804,612Source | 7,700,774Source | 3,140,925Source | 26,255,256Source |
| Interest Expense (non-operating)USD | 548,000Source | 179,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| General and Administrative ExpenseUSD | 12,132,000Source | 9,939,000Source | 8,544,000Source | 10,238,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -22,386,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 395,000Source | 711,000Source |
| Investment Income, InterestUSD | 116,000Source | 273,000Source | 400,000Source | 147,000Source |
| Nonoperating Income (Expense)USD | -7,088,000Source | 1,717,000Source | 5,000Source | -563,000Source |
| Operating ExpensesUSD | 20,511,000Source | 20,519,000Source | 18,234,000Source | 19,936,000Source |
| Operating Lease, ExpenseUSD | 400,000Source | 200,000Source | 200,000Source | 200,000Source |
| Research and Development ExpenseUSD | 8,379,000Source | 10,580,000Source | 9,690,000Source | — |
Offerings
Registration 333-296411
Registration 333-292637
- Gross proceeds
- 15000000.0
- Net proceeds
- 13950000.0
- Deal price
- 0.38
- Shares
- 39473684
- Offering price
- $0.38
- Ticker
- PSTV
Underwriters: Underwriter, Lake Street Capital Markets, LLC
Registration 333-292717
Registration 333-289526
Registration 333-288121
Filing attachments
cnsy-ex99_1.htm · 8-K · 2026-10-02
Corporate Presentation (NASDAQ:CNSY) September 30, 2026 Exhibit 99.1 Introduction Regarding Forward Looking Statements This presentation of Cerenome, Inc. (the “Company”) contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looking statements. These forwar…
Read attachment ↗d382364dex41.htm · 8-K · 2026-09-10
EX-4.1 2 d382364dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 EXECUTION VERSION FORM OF SENIOR SECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (A) IN THE ABSENCE OF (I) AN EFFECTIVE REGISTRATION S…
Read attachment ↗d382364dex991.htm · 8-K · 2026-09-10
EX-99.1 7 d382364dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment Capital will support continued CNSide ® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, September 10, 2026 (GLOBE NEWSWIRE) - Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an in…
Read attachment ↗pstv-ex99_1.htm · 8-K · 2026-08-14
EX-99.1 2 pstv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerenome Reports Second Quarter 2026 Financial Results and Business Update HOUSTON, August 14, 2026 - Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming busi…
Read attachment ↗d138711dex43.htm · S-3/A · 2026-06-05
Exhibit 4.3 INDENTURE DATED AS OF, 20 BETWEEN PLUS THERAPEUTICS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 …
Read attachment ↗pstv-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 pstv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) - Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces financial results for …
Read attachment ↗